Payment overview · 2025
General Payments
$1,336.23
64 reported records · 18 companies
Healthcare provider profile · identity verified
Mohammad Hafeez, M. D.
Allopathic & Osteopathic Physicians|Internal Medicine · SUFFERN, NY · NPI 1639101595
Verified facts
What the public records show
CMS Open Payments records show Mohammad Hafeez, M. D. received $1,336.23 in general payments during 2025 across 64 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Lumigan by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 359 claims for Eliquis by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $271.90 | 20.4% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $145.50 | 10.9% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $140.11 | 10.5% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.30 | 7.8% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $100.48 | 7.5% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $85.40 | 6.4% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $73.67 | 5.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.08 | 5.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.37 | 5.0% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $47.36 | 3.5% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $42.90 | 3.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.84 | 3.2% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$42.62 | 3.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.00 | 1.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.88 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.54 | 1.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.15 | 1.3% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.13 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,336.23 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $140.11 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $110.40 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $108.42 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $103.71 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $103.45 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $100.48 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $96.77 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $77.34 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $76.82 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $73.67 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $47.36 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $47.05 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.08 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.08 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $42.90 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $42.84 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 359 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 110 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
359 | 45 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 862 | 182 |
| Levothyroxine Sodium | Levothyroxine Sodium | 396 | 70 |
| Eliquis | Apixaban | 359 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 306 | 86 |
| Gabapentin | Gabapentin | 283 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 270 | 81 |
| Metformin Hcl | Metformin Hcl | 251 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 248 | 52 |
| Furosemide | Furosemide | 237 | 59 |
| Potassium Chloride | Potassium Chloride | 230 | 38 |
| Mirtazapine | Mirtazapine | 219 | 28 |
| Losartan Potassium | Losartan Potassium | 215 | 47 |
| Trazodone Hcl | Trazodone Hcl | 205 | 29 |
| Oxycodone Hcl | Oxycodone Hcl | 203 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 183 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 177 | 21 |
| Labetalol Hcl | Labetalol Hcl | 169 | 33 |
| Montelukast Sodium | Montelukast Sodium | 157 | 40 |
| Carvedilol | Carvedilol | 155 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 144 | 44 |
| Simvastatin | Simvastatin | 143 | 32 |
| Sertraline Hcl | Sertraline Hcl | 140 | 25 |
| Levetiracetam | Levetiracetam | 139 | 22 |
| Prednisone | Prednisone | 136 | 51 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 134 | 34 |
| Lisinopril | Lisinopril | 130 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 130 | 31 |
| Omeprazole | Omeprazole | 122 | 44 |
| Xarelto | Rivaroxaban | 121 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 120 | 12 |
| Alprazolam | Alprazolam | 115 | 23 |
| Donepezil Hcl | Donepezil Hcl | 111 | 11 |
| Jardiance | Empagliflozin | 110 | 25 |
| Sodium Chloride | 0.9 % Sodium Chloride | 110 | 20 |
| Glimepiride | Glimepiride | 107 | 33 |
| Famotidine | Famotidine | 106 | 28 |
| Azithromycin | Azithromycin | 102 | 67 |
| Januvia | Sitagliptin Phosphate | 102 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 15 |
| Allopurinol | Allopurinol | 100 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 29 |
| Buspirone Hcl | Buspirone Hcl | 97 | 13 |
| Midodrine Hcl | Midodrine Hcl | 95 | 24 |
| Lorazepam | Lorazepam | 93 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 16 |
| Latanoprost | Latanoprost | 81 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 77 | 17 |
| Baclofen | Baclofen | 76 | 11 |
| Budesonide | Budesonide | 74 | 18 |
| Clonidine Hcl | Clonidine Hcl | 74 | 20 |
| Tradjenta | Linagliptin | 72 | 12 |
| Tramadol Hcl | Tramadol Hcl | 72 | 15 |
| Ezetimibe | Ezetimibe | 71 | suppressed |
| Pregabalin | Pregabalin | 70 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 68 | suppressed |
| Nifedipine Er | Nifedipine | 68 | 20 |
| Risperidone | Risperidone | 67 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 30 |
| Spironolactone | Spironolactone | 59 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 58 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 28 |
| Farxiga | Dapagliflozin Propanediol | 55 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 55 | suppressed |
| Atenolol | Atenolol | 54 | 13 |
| Entresto | Sacubitril/Valsartan | 54 | suppressed |
| Daptomycin | Daptomycin | 53 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 51 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 50 | 13 |
| Lactulose | Lactulose | 48 | 18 |
| Mupirocin | Mupirocin | 47 | 22 |
| Repaglinide | Repaglinide | 47 | suppressed |
| Valsartan | Valsartan | 47 | 13 |
| Meropenem | Meropenem | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 14 |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | 14 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 43 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 43 | 12 |
| Levofloxacin | Levofloxacin | 42 | 27 |
| Nystatin | Nystatin | 42 | 27 |
| Acetazolamide | Acetazolamide | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 17 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 40 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 13 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 22 |
| Brimonidine Tartrate | Brimonidine Tartrate | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 12 |
| Torsemide | Torsemide | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 14 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | 11 |
| Nuplazid | Pimavanserin Tartrate | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | 16 |
| Ibuprofen | Ibuprofen | 30 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 17 |
| Memantine Hcl Er | Memantine Hcl | 29 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 29 | 16 |
| Silver Sulfadiazine | Silver Sulfadiazine | 29 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Insulin Lispro | Insulin Lispro | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 23 |
| Anastrozole | Anastrozole | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 13 |
| Haloperidol | Haloperidol | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Xtampza Er | Oxycodone Myristate | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 17 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 24 | suppressed |
| Demeclocycline Hcl | Demeclocycline Hcl | 23 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 23 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 13 |
| Nyamyc | Nystatin | 22 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Cyclosporine | Cyclosporine | 20 | suppressed |
| Lumigan | Bimatoprost | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Acetylcysteine | Acetylcysteine | 17 | suppressed |
| Alogliptin | Alogliptin Benzoate | 17 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Micafungin | Micafungin Sodium | 17 | suppressed |
| Naproxen | Naproxen | 17 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Xcopri | Cenobamate | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Restasis | Cyclosporine | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 16 | suppressed |
| Admelog Solostar | Insulin Lispro | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 12 |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Procrit | Epoetin Alfa | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Timolol Maleate | Timolol Maleate/Pf | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,336.23 · 64 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, CAPLYTA, CAPVAXIVE, ELIQUIS, ENTRESTO, FARXIGA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, REXULTI, TRELEGY ELLIPTA, VERQUVO, VRAYLAR, VYNDAQEL, Wegovy, XIFAXAN, XTAMPZA, YUPELRI, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error